Cash, cash equivalents and investments were $294.9 million as of December 31, 2024, as compared to $203.0 million as of December 31, 2023. Tourmaline anticipates that its current cash, cash equivalents, and investments will provide cash runway into the second half of 2027, funding its operations through key pacibekitug data readouts in cardiovascular inflammation and TED as well as other pacibekitug development activities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Robinhood initiated, MongoDB downgraded: Wall Street’s top analyst calls
- Wedbush bullish on Tourmaline Bio, initiates with an Outperform
- Tourmaline Bio initiated with an Outperform at Wedbush
- Tourmaline Bio initiated with an Outperform at LifeSci Capital
- Tourmaline Bio management to meet with Truist